CURE’s metastatic breast cancer page features the latest cancer news and updates on metastatic breast cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in metastatic breast cancer.
May 22nd 2024
The Food and Drug Administration granted a breakthrough therapy designation to inavolisib plus Ibrance and fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Phase 3 Trial of Fablyn Plus Verzenio for Metastatic Breast Cancer Initiates Registration
March 20th 2023Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.